Hydroxyurea (HU) has been shown to have a significantly positive clinical impact in individuals with SCD and is thought to primarily influence disease severity by increasing levels of fetal Hb (HbF) (18). The gene discussed is GSTM1; the disease is Schnyder corneal dystrophy.